Understanding Providers’ Readiness and Attitudes Toward Autoantibody Screening: A Mixed-Methods Study
Emma Ospelt, Holly Hardison, Nicole Rioles, Nudrat Noor, Ruth S. Weinstock, Kristina Cossen, Priyanka Mathias, Allison Smego, Nestoras Mathioudakis, Osagie Ebekozien, T1D Exchange Quality Improvement Collaborative
Abstract
Screening for autoantibodies associated with type 1 diabetes can identify people most at risk for progressing to clinical type 1 diabetes and provide an opportunity for early intervention. Drawbacks and barriers to screening exist, and concerns arise, as methods for disease prevention are limited and no cure exists today. The availability of novel treatment options such as teplizumab to delay progression to clinical type 1 diabetes in high-risk individuals has led to the reassessment of screening programs. This study explored awareness, readiness, and attitudes of endocrinology providers toward type 1 diabetes autoantibody screening.